Tower Research Capital (TRC)’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $74K | Sell |
9,348
-394
| -4% | -$2.52K | ﹤0.01% | 2426 |
|
|
2026
Q1 | $56.5K | Sell |
9,742
-998
| -9% | -$6.62K | ﹤0.01% | 2636 |
|
|
2025
Q4 | $84.3K | Buy |
10,740
+6,286
| +141% | +$49.5K | ﹤0.01% | 2055 |
|
|
2025
Q3 | $36.3K | Sell |
4,454
-12,941
| -74% | -$86K | ﹤0.01% | 2774 |
|
|
2025
Q2 | $81.2K | Buy |
17,395
+15,678
| +913% | +$71.8K | ﹤0.01% | 2553 |
|
|
2025
Q1 | $9.2K | Sell |
1,717
-2,218
| -56% | -$8.95K | ﹤0.01% | 3810 |
|
|
2024
Q4 | $13.3K | Buy |
3,935
+264
| +7% | +$849 | ﹤0.01% | 3535 |
|
|
2024
Q3 | $10.5K | Sell |
3,671
-21,923
| -86% | -$56.3K | ﹤0.01% | 3752 |
|
|
2024
Q2 | $57.6K | Buy |
25,594
+23,438
| +1,087% | +$47.2K | ﹤0.01% | 2991 |
|
|
2024
Q1 | $4.76K | Sell |
2,156
-25,692
| -92% | -$66.5K | ﹤0.01% | 4632 |
|
|
2023
Q4 | $65.4K | Buy |
27,848
+9,733
| +54% | +$18K | ﹤0.01% | 2951 |
|
|
2023
Q3 | $33.7K | Buy |
18,115
+13,688
| +309% | +$31.4K | ﹤0.01% | 2918 |
|
|
2023
Q2 | $11.6K | Sell |
4,427
-4,534
| -51% | -$11.5K | ﹤0.01% | 3960 |
|
|
2023
Q1 | $14K | Sell |
8,961
-9,906
| -53% | -$12.4K | ﹤0.01% | 3927 |
|
|
2022
Q4 | $25K | Sell |
18,867
-53,990
| -74% | -$76.2K | ﹤0.01% | 2936 |
|
|
2022
Q3 | $114K | Buy |
72,857
+40,913
| +128% | +$67.7K | ﹤0.01% | 2458 |
|
|
2022
Q2 | $49K | Buy |
31,944
+15,465
| +94% | +$32.6K | ﹤0.01% | 2910 |
|
|
2022
Q1 | $42K | Buy |
16,479
+7,079
| +75% | +$17.3K | ﹤0.01% | 2877 |
|
|
2021
Q4 | $28K | Buy |
9,400
+3,465
| +58% | +$7.48K | ﹤0.01% | 3317 |
|
|
2021
Q3 | $15K | Buy |
5,935
+2,593
| +78% | +$7.53K | ﹤0.01% | 4004 |
|
|
2021
Q2 | $14K | Sell |
3,342
-6,222
| -65% | -$23.7K | ﹤0.01% | 4195 |
|
|
2021
Q1 | $43K | Sell |
9,564
-5,282
| -36% | -$28.5K | ﹤0.01% | 3259 |
|
|
2020
Q4 | $73K | Sell |
14,846
-25,739
| -63% | -$129K | ﹤0.01% | 2684 |
|
|
2020
Q3 | $241K | Buy |
40,585
+33,022
| +437% | +$132K | ﹤0.01% | 2401 |
|
|
2020
Q2 | $20K | Buy |
7,563
+5,423
| +253% | +$18.9K | ﹤0.01% | 3689 |
|
|
2020
Q1 | $4K | Sell |
2,140
-5,653
| -73% | -$24.3K | ﹤0.01% | 2408 |
|
|
2019
Q4 | $55K | Buy |
7,793
+7,267
| +1,382% | +$60K | ﹤0.01% | 1283 |
|
|
2019
Q3 | $5K | Sell |
526
-3,145
| -86% | -$35.3K | ﹤0.01% | 3347 |
|
|
2019
Q2 | $42K | Buy |
+3,671
| New | +$38.5K | ﹤0.01% | 1712 |
|
|
2019
Q1 | – | Sell |
-1,016
| Closed | -$17K | – | 4341 |
|
|
2018
Q4 | $17K | Sell |
1,016
-3,072
| -75% | -$61.6K | ﹤0.01% | 2073 |
|
|
2018
Q3 | $72K | Buy |
+4,088
| New | +$88.7K | 0.01% | 1543 |
|
Other funds holding XERS
RA
Tower Research Capital (TRC)'s XERS Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Xeris Biopharma Holdings (XERS) stake by 4% in Q2 2026, selling an estimated $2.52K and leaving 9,348 shares worth $74K. The position accounts for ﹤0.01% of the portfolio, ranked #2426.
Tower Research Capital (TRC) first reported a position in XERS in Q3 2018 and has held it in 31 quarters since. The position peaked at $241K in Q3 2020. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- Tower Research Capital (TRC) held 9,348 shares of Xeris Biopharma Holdings worth $74K as of Q2 2026.
- Tower Research Capital (TRC) sold 394 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.52K.
- Xeris Biopharma Holdings made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2426 holding.
- Tower Research Capital (TRC) first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 31 quarters since.
- Tower Research Capital (TRC)'s Xeris Biopharma Holdings position peaked at $241K in Q3 2020.
- 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.